Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.86 and traded as high as $3.10. Sonoma Pharmaceuticals shares last traded at $3.00, with a volume of 241,042 shares traded.

Sonoma Pharmaceuticals Stock Up 4.9 %

The stock has a market capitalization of $57.01 million, a PE ratio of -4.11 and a beta of 1.37. The stock has a fifty day moving average of $2.06 and a 200-day moving average of $0.86.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The firm had revenue of $3.39 million for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 65.66% and a negative net margin of 35.91%. Equities research analysts expect that Sonoma Pharmaceuticals, Inc. will post -4 EPS for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.